3190 results for «3537»
3190 results
Mastering techniques from basic to complex - TAVI basics
13 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a comprehensive overview of Transcatheter Aortic Valve Implantation (TAVI) fundamentals, focusing on CT scan analysis for optimal patient and valve selection, strategies to avoid procedural complications, and approaches to streamline TAVI procedures for improved outcomes.
Patient-tailored treatment for bicuspid valve
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into patient-tailored treatment strategies for bicuspid aortic valve stenosis, focusing on evidence-based valve selection and sizing for TAVI candidates. This session reviews current device options, procedural planning considerations, and case studies illustrating the use of balloon-expanding and self-expanding valves, emphasizing challenges posed by unfavourable bicuspid...
Mitral TEER masterclass
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the mitral TEER masterclass focusing on unique anatomical challenges encountered in Asian populations. This session presents complex case studies illustrating device strategies and practical techniques aimed at minimizing complications and optimizing procedural outcomes in anatomically challenging scenarios.
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
PCR Tokyo Valves 2026 Closing Ceremony
15 Feb 2026 – From PCR Tokyo Valves 2026
The Closing Ceremony marks the conclusion of this cardiology conference, providing a formal wrap-up and reflection on the key highlights and advancements presented throughout the event. It serves as an opportunity to acknowledge contributors and set the stage for future initiatives in interventional cardiology.
Mastering techniques from basic to complex - Mitral regurgitation assessment and suitability for TEER
13 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the assessment of mitral regurgitation and the criteria determining suitability for Transcatheter Edge-to-Edge Repair (TEER). This session reviews mitral valve anatomy and the latest clinical data supporting mitral TEER interventions.
Mastering techniques from basic to complex - Tips and tricks for advanced mitral TEER: anatomy and imaging
13 Feb 2026 – From PCR Tokyo Valves 2026
Advance your expertise in mitral TEER by gaining anatomical insights, understanding device interaction with native valve structures, and learning to prevent and manage procedural complications through case-based imaging and live assessments.
Mastering techniques from basic to complex - Tricuspid TEER fundamentals
13 Feb 2026 – From PCR Tokyo Valves 2026
Gain foundational knowledge in tricuspid TEER by understanding anatomical criteria for patient suitability, key procedural steps, and device techniques, enhanced by simulation-based procedural training.
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Patient selection for tricuspid TEER in 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...
Procedural optimisation for enhanced acute and long-term outcomes
14 Feb 2026 – From PCR Tokyo Valves 2026
This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...
Complications and bailout strategies in transcatheter mitral interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.
Transcatheter electrosurgery and leaflet modification of the aortic valve
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...
TAVI: new evidence and clinical trials
14 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest evidence from head-to-head clinical trials comparing contemporary TAVI devices, including detailed discussions of the LANDMARK and COMPARE trials. It also highlights ongoing and upcoming clinical trials poised to influence guideline recommendations and expand the therapeutic scope of TAVI, providing crucial insights...
Team approach to structural heart disease: how to handle unexpected situations
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...
From diagnosis to device: decision-making and planning for mitral valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a structured approach to mitral TEER, integrating advanced imaging techniques for detailed mitral valve morphology evaluation, procedural planning, and complication prediction. It highlights device selection considerations and emerging technologies to tailor interventions for complex mitral valve disease, supported by multiple case presentations and...
Healthcare professionals in the structural heart disease treatment
15 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the essential roles and contributions of various healthcare professionals involved in structural heart disease treatment. It offers insights into the unique responsibilities of medical technologists, nurses, and radiological technologists across preoperative, intraoperative, and postoperative stages, fostering collaboration and sharing practical tips to strengthen...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
